QS Investors’s Akebia Therapeutics AKBA Stock Holding History

QS Investors’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$463K	Buy	+122,000	New	+$411K	0.01%	768
2019 Q3	–	Sell	-202	Closed	-$1K	–	1632
2019 Q2	$1K	Hold	202	–	–	﹤0.01%	1627
2019 Q1	$2K	Hold	202	–	–	﹤0.01%	1629
2018 Q4	$2K	Hold	202	–	–	﹤0.01%	1631
2018 Q3	$2K	Hold	202	–	–	﹤0.01%	1652
2018 Q2	$2K	Buy	202 +15	+8%	+$150	﹤0.01%	1673
2018 Q1	$2K	Buy	187 +26	+16%	+$364	﹤0.01%	1674
2017 Q4	$2K	Buy	+161	New	+$2.67K	﹤0.01%	1678

Other funds holding AKBA

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AIM

Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

QS Investors's AKBA Position: Q2 2021 in Review

QS Investors opened a new position in Akebia Therapeutics (AKBA) in Q2 2021: 122,000 shares worth $463K. The stake represents 0.01% of the portfolio and ranks #768 among its holdings. This is a return to the name: QS Investors previously reported a position in AKBA as recently as Q2 2019.

QS Investors first reported a position in AKBA in Q4 2017 and has held it in 8 quarters since. 139 funds tracked by Wall St. Rank hold AKBA as of Q2 2021.

QS Investors held 122,000 shares of Akebia Therapeutics worth $463K as of Q2 2021.
Akebia Therapeutics was a new QS Investors position in Q2 2021.
Akebia Therapeutics made up 0.01% of QS Investors's portfolio in Q2 2021, its #768 holding.
QS Investors first reported a position in Akebia Therapeutics in Q4 2017 and has held it in 8 quarters since.
139 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2021.

Based on QS Investors's 13F filing for Q2 2021, filed 13 Aug 2021.